Journal article
Impact of visit-to-visit glycemic variability on the risks of macrovascular and microvascular events and all-cause mortality in type 2 diabetes: The ADVANCE trial
Y Hirakawa, H Arima, S Zoungas, T Ninomiya, M Cooper, P Hamet, G Mancia, N Poulter, S Harrap, M Woodward, J Chalmers
Diabetes Care | Published : 2014
DOI: 10.2337/dc14-0199
Abstract
OBJECTIVE: There is no consensus on the importance of visit-to-visit glycemic variability in diabetes. Therefore, we assessed the effects of visit-to-visit variability (VVV) in HbA1c and fasting glucose on major outcomes in the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation) trial. RESEARCH DESIGN AND METHODS: ADVANCE was a factorial randomized controlled trial of intensive glucose control and blood pressure lowering in patients with type 2 diabetes. VVV in the intensive glucose treatment group was defined using the SD of five measurements of HbA1c and glucose taken 3-24 months after randomization. Outcomes were combined macro- and microvasc..
View full abstractGrants
Funding Acknowledgements
The ADVANCE trial was funded by a grant from the National Health and Medical Research Council (NHMRC) of Australia. Y.H. holds a Research Fellowship Award from the Uehara Memorial Foundation for research activities. H. A. holds a Future Fellowship from the Australian Research Council. M. C. holds an Australia Fellowship from the NHMRC. M. W. holds a Senior Research Fellowship from the NHMRC.